Differential Diagnosis for Hot Flashes in Elderly Males

Primary Differential Considerations

50-80% of men on androgen deprivation therapy (ADT) experience hot flashes, which can persist even after treatment discontinuation, according to the National Comprehensive Cancer Network 1
The American College of Physicians recommends that ADT is the main therapeutic approach for metastatic prostate cancer and may be used as adjuvant therapy, with associated gynecomastia varying by ADT method 1
Hot flashes from ADT are associated with impotence, gynecomastia, and decreased testicle size, with a 43% absolute risk increase in impotence, as reported by the American College of Physicians 2
The Endocrine Society suggests that hot flashes are a recognized symptom of male hypogonadism that should improve with testosterone normalization, and recommends confirmatory diagnosis with repeat morning total testosterone measurement and free testosterone by equilibrium dialysis 3

The American Urological Association recommends essential laboratory testing, including morning total testosterone, free testosterone by equilibrium dialysis, LH and FSH levels, and serum prolactin, to diagnose hypogonadism and rule out prostate cancer 3
A critical history should include current or past ADT use for prostate cancer, timing and frequency of hot flashes relative to any cancer treatment, and associated symptoms such as gynecomastia and erectile dysfunction, as suggested by the National Comprehensive Cancer Network 1

The American College of Physicians advises against assuming all hot flashes in elderly men are benign age-related changes, and recommends evaluation for hypogonadism and occult prostate cancer requiring ADT 3
The Endocrine Society recommends against starting testosterone replacement without ruling out prostate cancer, as androgens are contraindicated in men with advanced prostate cancer 4

Gabapentin reduces hot flash severity by 46% at 8 weeks versus 15% with placebo, and is beneficial for patients with neuropathic pain, as seen in a study published in the Annals of Oncology in 2008 5
Venlafaxine 37.5 mg/day reduces hot flashes by 61% at 75 mg dose, according to a study published in the Annals of Oncology in 2008, and may be considered as an alternative pharmacological option 6
Paroxetine 10-12.5 mg/day reduces hot flash composite score by 62-65%, as reported in the Annals of Oncology in 2008, but should be used with caution due to the risk of serotonin syndrome 6
Clonidine reduces hot flashes by only 46% and causes problematic side effects, with 40% discontinuation rates, as noted in a study published in the Annals of Oncology in 2008 5

Reassess symptom severity in 1-2 weeks after gabapentin dose optimization, as patients recognize efficacy within days, according to a study published in the Annals of Oncology in 2008 5
If no improvement after 4-6 weeks at maximum tolerated gabapentin dose, consider switching to venlafaxine or paroxetine, as recommended in a study published in the Annals of Oncology in 2008 6